Market Cap 10.07B
Revenue (ttm) 2.36B
Net Income (ttm) 341.30M
EPS (ttm) N/A
PE Ratio 30.81
Forward PE 26.50
Profit Margin 14.49%
Debt to Equity Ratio 0.00
Volume 1,935,200
Avg Vol 1,541,550
Day's Range N/A - N/A
Shares Out 98.94M
Stochastic %K 84%
Beta 0.33
Analysts Strong Sell
Price Target $160.08

Latest News on NBIX

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?

Feb 7, 2025, 1:05 PM EST - 2 months ago

Why Is Neurocrine Biosciences Stock Trading Lower On Friday?


US FDA approves Neurocrine Biosciences' genetic disorder drug

Dec 13, 2024, 5:50 PM EST - 4 months ago

US FDA approves Neurocrine Biosciences' genetic disorder drug